The American Diabetes Association has issued strong warnings against using non-FDA-approved compounded GLP-1 and dual GIP/GLP-1 products, and the same caution applies even more strongly to investigational medications like retatrutide
Unsealed bottles or damaged packaging means contamination risk
Food and Drug Administration (FDA) pronouncing the drugs in shortage, compounding pharmacies have stepped in to fill the void, but that may cloud the situation, not clarify it
Most qualified providers recommend optimizing a single GLP-1 agonist (or another evidence-based monotherapy) before exploring experimental combinations
Muscle tension in the neck and throat, hypervigilance to bodily sensations, and rapid breathing patterns all contribute
Some people, particularly at lower doses of Wegovy , notice barely any difference